Key Points
- Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares on May 18 at an average price of $59.07, totaling about $607,830. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Agarwal still owned 16,406 shares valued at about $969,102, but his stake fell by 38.55%. He also made a smaller sale in March of 395 shares.
- The stock was trading lower in the session, while analysts remain broadly positive overall: Oruka has a Moderate Buy consensus rating and a consensus price target of $120.80. The company recently beat quarterly EPS expectations, reporting a loss of $0.48 per share versus estimates for a $0.52 loss.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,290 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the sale, the senior vice president directly owned 16,406 shares of the company's stock, valued at $969,102.42. This trade represents a 38.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Monday, March 16th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $41.30, for a total value of $16,313.50.
Oruka Therapeutics Trading Down 5.8%
Shares of NASDAQ:ORKA opened at $58.34 on Tuesday. Oruka Therapeutics, Inc. has a 1 year low of $9.54 and a 1 year high of $91.00. The business has a fifty day simple moving average of $55.67 and a 200 day simple moving average of $39.63. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of -30.07 and a beta of -0.20.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.15 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on ORKA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Barclays raised their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a report on Monday, April 27th. UBS Group raised their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, April 28th. BTIG Research restated a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 14th. Finally, Wedbush set a $165.00 target price on Oruka Therapeutics in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $120.80.
Check Out Our Latest Report on Oruka Therapeutics
Hedge Funds Weigh In On Oruka Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC increased its stake in Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock valued at $1,476,000 after acquiring an additional 420 shares during the period. AlphaCentric Advisors LLC increased its stake in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company's stock valued at $564,000 after acquiring an additional 626 shares during the period. Russell Investments Group Ltd. increased its stake in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock valued at $92,000 after acquiring an additional 788 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Oruka Therapeutics by 62.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company's stock valued at $71,000 after buying an additional 904 shares during the period. Institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
